Patents Assigned to Children's Medical Center Corporation
  • METHODS AND COMPOSITIONS FOR ALLELE SPECIFIC GENE EDITING
    Publication number: 20220112504
    Abstract: The invention provides compositions and methods for allele specific gene editing. In particular, the invention provides methods and compositions for treating dominant progressive hearing loss by selectively inactivating a dominant mutation in TMC1.
    Type: Application
    Filed: December 20, 2021
    Publication date: April 14, 2022
    Applicants: Children's Medical Center Corporation, President and Fellows of Harvard College
    Inventors: Jeffrey R. HOLT, Bence GYORGY
  • CD1a ANTIBODIES AND USES THEREOF
    Publication number: 20220112291
    Abstract: Antibodies, and antigen-binding fragments thereof, that specifically bind to Cluster of Differentiation 1a (CD1a) are provided. Embodiments include uses, and associated methods of using the antibodies, and antigen-binding fragments thereof.
    Type: Application
    Filed: October 7, 2021
    Publication date: April 14, 2022
    Applicants: Pfizer Inc., Children's Medical Center Corporation
    Inventors: Florian WINAU, Oleg V. KOVALENKO, Chew Shun CHANG, Di WU, Nicholas Andrew MARZE, Shian-Huey CHIANG
  • Methods for predicting anti-cancer response
    Patent number: 11299782
    Abstract: The present invention is based, in part, on the identification of novel methods for defining predictive biomarkers of response to anti-cancer drugs.
    Type: Grant
    Filed: December 28, 2018
    Date of Patent: April 12, 2022
    Assignees: Children's Medical Center Corporation, The Technical University of Denmark, Dana-Farber Cancer Institute, Inc., The Brigham and Women's Hospital, Inc.
    Inventors: Zoltan Szallasi, Nicolai Juul Birkbak, Aron Eklund, Daniel Silver, Zhigang Wang, Andrea Richardson
  • Prevention and treatment of diabetic nephropathy
    Patent number: 11291641
    Abstract: Embodiments herein disclose methods relating to diabetic nephropathy (DN); methods for preventing the onset and also for preventing the progressing of DN, as well as the treatment of DN in diabetic subjects comprising administering reparixin and/or ladarixin which are inhibitors of CXCL8 receptor CXCR1 and CXCR2 activation.
    Type: Grant
    Filed: October 3, 2017
    Date of Patent: April 5, 2022
    Assignees: THE CHILDREN'S MEDICAL CENTER CORPORATION, DOMPE FARMACEUTICI S.P.A.
    Inventors: Paolo Fiorina, Roberto Bassi, Andrea Vergani, Marcello Allegretti
  • METHODS AND COMPOSITIONS RELATING TO MESENCHYMAL STEM CELL EXOSOMES
    Publication number: 20220096560
    Abstract: The invention provides compositions comprising mesenchymal stem cell (MSC) derived exosomes, and methods of their use in subjects having certain lung diseases including inflammatory lung disease.
    Type: Application
    Filed: October 1, 2021
    Publication date: March 31, 2022
    Applicant: Children's Medical Center Corporation
    Inventors: S. Alexander Mitsialis, Changjin Lee, Stella Kourembanas
  • COLLAGEN SCAFFOLDS
    Publication number: 20220096710
    Abstract: Methods for preparing and using collagen extracts and collagen scaffolds are provided. Additionally, methods and related kits for the repair of articular tissue using the collagen material are provided.
    Type: Application
    Filed: November 4, 2021
    Publication date: March 31, 2022
    Applicant: The Children's Medical Center Corporation
    Inventor: Martha M. MURRAY
  • Botulinum neurotoxin and its derivatives
    Patent number: 11286473
    Abstract: Provided herein are Clostridial Botulinum neurotoxin (BoNT) polypeptides of a novel serotype (BoNT/X) and methods of making and using the BoNT polypeptides, e.g., in therapeutic applications.
    Type: Grant
    Filed: July 7, 2017
    Date of Patent: March 29, 2022
    Assignee: Children's Medical Center Corporation
    Inventors: Min Dong, Sicai Zhang, Paul Stenmark
  • Instrument port with fluid flush system
    Patent number: 11284788
    Abstract: In at least some aspects, an instrument port for introducing an instrument into a surgical site comprises: a port body having: an instrument channel extending through the port body; and a plurality of fluid flush channels each separate from one another and the instrument channel, each extending along a major portion of the port body and in fluid communication with the instrument channel; and a bulb comprising a bulb channel extending through the bulb, the bulb channel aligned with the instrument channel, wherein the bulb channel and instrument channel are configured to receive the instrument.
    Type: Grant
    Filed: March 9, 2018
    Date of Patent: March 29, 2022
    Assignee: The Children's Medical Center Corporation
    Inventors: Anthony Maiorano, Jeffrey C. Cerier
  • Methods of Epigenetic Analysis
    Publication number: 20220090176
    Abstract: The present invention provides for methods of epigenetic analysis. In some cases, the methods may include obtaining a sample comprising a nucleic acid sequence. In some cases, the nucleic acid sequence may comprise one or more epigenetic marks. The methods may include performing a sequencing. The methods may include distinguishing a hydroxymethylated base from a methylated base.
    Type: Application
    Filed: November 17, 2021
    Publication date: March 24, 2022
    Applicants: The Children's Medical Center Corporation, The United States of America, As Represented by the Secretary, Department of Health & Human Services
    Inventors: Anjana Rao, Mamta Tahiliani, Kian Peng Koh, Suneet Agarwal, Aravind Iyer
  • Modified alginates for anti-fibrotic materials and applications
    Patent number: 11266606
    Abstract: Covalently modified alginate polymers, possessing enhanced biocompatibility and tailored physiochemical properties, as well as methods of making and use thereof, are disclosed herein. The covalently modified alginates are useful as a matrix for coating of any material where reduced fibrosis is desired, such as encapsulated cells for transplantation and medical devices implanted or used in the body.
    Type: Grant
    Filed: September 26, 2019
    Date of Patent: March 8, 2022
    Assignees: MASSACHUSETTS INSTITUTE OF TECHNOLOGY, THE CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Arturo J. Vegas, Joshua C. Doloff, Omid Veiseh, Minglin Ma, Robert S. Langer, Daniel G. Anderson
  • MODIFIED INTEGRIN POLYPEPTIDES, MODIFIED INTEGRIN POLYPEPTIDE DIMERS, AND USES THEREOF
    Publication number: 20220064261
    Abstract: Described herein are modified integrin ? and/or ? headpiece polypeptides, and crystallizable integrin polypeptide dimers comprising a modified integrin ? and/or ? headpiece polypeptide and a disulfide bond linking the two integrin headpiece polypeptide subunits. Methods for using the modified integrin ? and/or ? headpiece polypeptides and the integrin polypeptide dimers are also provided herein. For example, methods for characterizing integrin-ligand interaction and identifying integrin ligands are also provided herein. In some embodiments, the identified integrin ligands can be used as inhibitors of integrins.
    Type: Application
    Filed: July 23, 2021
    Publication date: March 3, 2022
    Applicant: THE CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Timothy Alan SPRINGER, Xianchi Dong, Chafen Lu
  • Hematopoietic stem and progenitor cells derived from hemogenic endothelial cells
    Patent number: 11261430
    Abstract: Embodiments herein relate to in vitro production methods of hematopoietic stem cell (HSC) and hematopoietic stem and progenitor cell (HSPC) that have long-term multilineage hematopoiesis potentials upon in vivo engraftment. The HSC and HSPCs are derived from pluripotent stem cells-derived hemogenic endothelia cells (HE).
    Type: Grant
    Filed: May 3, 2017
    Date of Patent: March 1, 2022
    Assignee: THE CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: George Q. Daley, Ryohichi Sugimura
  • Engineered liposomes as cancer-targeted therapeutics
    Patent number: 11260132
    Abstract: The disclosure provides liposomes (e.g., cancer-targeting liposomes) with ligands (e.g., EGFR ligands and ICAM-1 ligands) conjugated to liposome surfaces. In some embodiments, the molecular ratio of different ligands complement the relative molecular density (i.e., ratio) of overexpressed protein on the surface of a cell targeted by the liposome (e.g., cancer cell).
    Type: Grant
    Filed: March 16, 2018
    Date of Patent: March 1, 2022
    Assignee: Children's Medical Center Corporation
    Inventors: Marsha A. Moses, Peng Guo, Jiang Yang, Debra Auguste, Daxing Liu
  • Vectors and compositions for treating hemoglobinopathies
    Patent number: 11261441
    Abstract: The invention provides improved gene therapy vectors, compositions, and methods.
    Type: Grant
    Filed: March 29, 2018
    Date of Patent: March 1, 2022
    Assignees: bluebird bio, Inc., Children's Medical Center Corporation
    Inventors: Gabor Veres, David A. Williams
  • COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES
    Publication number: 20220055993
    Abstract: The present disclosure provides compounds of Formula (I). The compounds described herein may be useful in treating and/or preventing proliferative diseases (e.g., cancer). Also provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including or using a compound described herein.
    Type: Application
    Filed: May 4, 2021
    Publication date: February 24, 2022
    Applicants: Children's Medical Center Corporation, Beth Israel Deaconess Medical Center, Inc.
    Inventors: Bruce R. Zetter, Lijun Sun
  • COMPOSITIONS AND METHODS TO TREATING HEMOGLOBINOPATHIES
    Publication number: 20220056453
    Abstract: Embodiments herein provide specially designed synthetic BCL11A-targeting microRNAs for RNA polymerase II expression, and methods of use to treat hemoglobinopathies such as sickle cell disease or thalassemia by increasing the expression levels of fetal hemoglobin levels.
    Type: Application
    Filed: August 17, 2021
    Publication date: February 24, 2022
    Applicant: THE CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Michael MILSOM, David A. WILLIAMS, Richard GREGORY
  • Botulinum neurotoxin and its derivatives
    Patent number: 11248218
    Abstract: Provided herein are Clostridial Botulinum neurotoxin (BoNT) polypeptides of a novel serotype (BoNT/X) and methods of making and using the BoNT polypeptides, e.g., in therapeutic applications.
    Type: Grant
    Filed: July 7, 2017
    Date of Patent: February 15, 2022
    Assignee: Children's Medical Center Corporation
    Inventors: Min Dong, Sicai Zhang, Paul Stenmark
  • COMPOSITIONS WITH PERMEATION ENHANCERS FOR DRUG DELIVERY
    Publication number: 20220040309
    Abstract: The present invention provides compositions and methods for delivery of therapeutic agents across an barrier. The compositions include a therapeutic agent (e.g., antimicrobial agent, antibiotic, or anesthetic agent), a permeation enhancer which increases the flux of the therapeutic agent across the barrier, and a matrix forming agent. The matrix forming agent forms a gel at a suitable gelation temperature and rheological properties for use in drug delivery, and in some cases, the gelation temperature and rheological properties are not significantly changed from those of the composition without the permeation enhancer. The invention also provides a matrix forming agent and compositions thereof. Such compositions are particularly useful in the treatment of otitis media. Methods of treatment, methods of delivery, and kits for the compositions described herein are also provided.
    Type: Application
    Filed: July 23, 2021
    Publication date: February 10, 2022
    Applicants: Children's Medical Center Corporation, Massachusetts Institute of Technology
    Inventors: Daniel S. Kohane, Rong Yang, Lily Yun Lin
  • CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE
    Publication number: 20220041552
    Abstract: The invention provides compounds, compositions, methods, and kits for the treatment of pain, itch, and neurogenic inflammation.
    Type: Application
    Filed: October 25, 2021
    Publication date: February 10, 2022
    Applicants: President and Fellows of Harvard College, Children's Medical Center Corporation
    Inventors: Bruce P. Bean, Clifford J. Woolf, Jinbo Lee, Sooyeon Jo, David P. Roberson, Sebastien Talbot
  • MiRNA targets
    Patent number: 11242553
    Abstract: The present invention provides systems and methods for identifying, isolating, and/or characterizing microRNAs, their targets, and microRNA response elements, and for predicting their biological function.
    Type: Grant
    Filed: January 17, 2014
    Date of Patent: February 8, 2022
    Assignee: Children's Medical Center Corporation
    Inventors: Judy Lieberman, Shen Mynn Tan